Thursday, August 06, 2026

Nobody Cares

Look around you.  Today,  tomorrow, look around. 

Supermarket, post office, gym, WalMart, Lowes, anywhere.

Nobody is thinking about you.  They don't care, never will.  They are too busy thinking about themselves.

Do not, ever, give a single shit about the judgement of people who have never, once, thought about you.

Stop you fear.  Who gives a shit?

Winners win, nobody cares.

Losers lose, nobody cares.

It is too easy these days.

Follow your dreams.

Work hard. 

You can do whatever it is you think you can do.

Think.



Never Stop Hammering


 

Government @WORK

Attending 4 high schools in three different states, while living on Indian Reservations, allowed me to see Government at work. 



Toby Rogers straight talk, no bullshit

"Every step was designed to inflict maximum harm: • Splicing HIV into a coronavirus. • Blocking access to hydroxychloroquine and ivermectin. • Removing NAC from Amazon and supermarket shelves. • No early treatment. • Ventilators that killed 90% of patients. • Seeding nursing homes with Covid+ patients. • Blanket Do-Not-Resuscitate orders for the disabled. • "15 days to flatten the curve" that slowed the rate of natural immunity. • Closing schools for two years. • Masks that reduced oxygen. • Shutting down gyms. • Keeping liquor stores open. • Closing hiking trails and parks thus preventing people from getting vitamin D. • Remdesivir and Paxlovid that are expensive, useless, and deadly. • The most toxic and deadly vaccines in history on a new platform that will never work. • Billions of dollars spent on propaganda to convince people to accept every step of this nefarious plan. • Firings, censorship, and blacklisting of critical thinkers. 

Covid is a world war, launched by the ruling class, against humanity."

Wednesday, August 05, 2026

Thank you David!

Met David Ryan in 1996 at the Ritz Carleton in Buckhead.

In 1996 I had met Dave Ryan at the Ritz Carleton in Atlanta and from that meeting we agreed I was to fly to Los Angeles to meet Bill as they were making a decision on what to do with their fund.  I believe David was running it at the time and I was being interviewed to represent their NEW USA mutual fund.   The fund had been launched in 1992 and was sold to MFS in 1997. 

David Ryan’s ANTS is a technical indicator/screener (not a formal ranking system like a persistent index) he developed while managing the New USA Growth Fund at William O’Neil + Company. It flags individual stocks showing signs of strong institutional accumulation over a short (~15-trading-day / 3-week) window:

  • Up on at least 12 of the past 15 days (momentum).
  • Price up ~20–25% over that period.
  • Volume up ~20–25% (or higher average volume) over that period.

These “ants” (small marks originally plotted on charts) often appear early in big winners as large buyers accumulate positions gradually without spiking the price too fast. It is available as a list or chart marker on IBD MarketSurge, and as free/paid indicators/screeners on TradingView (including versions developed with Ryan’s input), Deepvue, and similar platforms. It is a dynamic, short-term stock-selection tool used within a broader CAN SLIM / growth-momentum approach, not something that produces a stable, rebalanced basket suitable for an ETF.

Big Pharma Criminals


 

ONDAS

2026 revenue target: at least $525M (consensus ~$525.6M) — excludes Cyberhawk

Q1: $50.1M | Q2 est: ~$63–70M → ~$405M+ still needed in H2 • DZYNE closed July 2 | Next report: Aug 13
Pro forma backlog: $457M + $70M new orders in the following 4 weeks 
Q1 adj. EBITDA loss: $10.9M (vs $7.5M prior year)
Mgmt: Q2 expected peak of losses | DZYNE expected positive EBITDA in 2026
Q1 GAAP net income ~$361.2M driven by $389.5M noncash warrant gain
  DZYNE deal: $875.8M ($200M cash + ~40M shares now + ~45M shares Jan 4 2027 ≈ 8% dilution)
Cyberhawk: ~$125M deal (~95% cash, expected Q3 close)
Liquidity last reported: $1.48B (Q1 end, pre full deal impacts)
Closed $8.37 (Aug 3) → $4.77B market cap ≈ 9.1x 2026 revenue (excludes pending shares)
Avg targets: $16.75 (MarketBeat, 9 analysts) | ~$19.8 (other sources, 7–8 analysts)